Parkinson’s disease (PD) is a multisystem disease in which both the central nervous system (CNS) and peripheral nervous system (PNS) are affected. It is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta as the result of abnormal accumulation and aggregation of α‐synuclein (α‐syn) in the form of Lewy bodies and Lewy neurites. 1 α‐Syn plays an important role in the pathogenesis of neurodegenerative diseases and is considered to be the pathological hallmark of PD and Lewy body dementia. 2
α‐Syn is expressed in neurons (both the CNS and PNS) as well as in erythrocytes and most immune cells. Indeed, several studies have shown that α‐syn is upregulated after immune stimulation. 3 , 4 , 5 Recent reports have shown significant deficiency in T cell development in α‐syn knock‐out mice, which implicates α‐syn in both the development of B‐lymphocytes 6 and in regulation of T cell phenotypes and function. It has multiple immunomodulatory functions, which can promote disease pathogenicity and also offer protection against proinflammatory responses. 7 In addition, it has been shown that α‐syn can also facilitate immune reactions against infections. 8 Moreover, yet little is known about the innate neuron‐specific inhibitors of viral infections in the CNS.
Neuronal expression of α‐syn restricts the replication of RNA viruses and protects mice from virus‐induced neuronal injury. By contrast, in the absence of α‐syn, endoplasmic reticulum stress signaling was significantly altered in mice contaminated by neurotrophic RNA viruses, such as West Nile virus and Venezuelan equine encephalitis. 3 This supports the hypothesis that α‐syn may play an important role in immune defense responses. 4 In addition, it has been hypothesized that the α‐syn inhibits viral neuroinvasion from the PNS to the CNS. 9
Microglia are the resident immune cells of the brain; they play a major role in the neuroinfilammatory process with a high phagocytic capacity. 10 It has been shown that a reduction of the α‐syn expression level in microglia highly increases their response to lipopolysaccharides, whereas it decreases their phagocytic ability. 11 This is a consequence of overactivation of phospholipase D2 and cyclooxygenase‐2, which suggests that α‐syn is implicated in lipid‐mediated signaling by microglia. 12 Moreover, α‐syn may be an activating extracellular ligand for microglia. 12 This supports the findings mentioned previously in relation to its neuroprotective effect. 3
Coronavirus 2019 (COVID‐19) can infect neurons and cause disease. 13 It has been shown that it induces neurological diseases such as polyneuropathy, encephalitis, aortic ischemic stroke, and other neurological diseases. 14 , 15 Neurological manifestations of COVID‐19 infection have been classified into 2 categories: CNS and PNS manifestations. CNS symptoms include dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and epilepsy. However, PNS symptoms are less severe and include hyposmia, hypoplasia, neuralgia, and hypogeusia. 16
Taken together, the evidence noted previously suggests that the overexpression of α‐syn in patients suffering from PD might prevent neuroinvasion by the coronavirus, possibly by inhibiting the spread of the virus from the PNS to the CNS. Consistent with this hypothesis, a retrospective cohort study conducted in Japan showed that patients with parkinsonism hospitalized for pneumonia had a lower rate of in‐hospital mortality. 17 This hypothesis can be confirmed by using a large cohort of patients with PD experiencing a severe acute respiratory syndrome attributed to COVID‐19 infection.
Author Roles
(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique.
S.A.: 1A, 1B, 1C, 3A, 3B
A.A.: 1A, 1B, 1C, 3A, 3B
Z.O.: 1B, 1C, 3A, 3B
M.E.: 1B, 3A, 3B
A.B.: 1B, 3B
M.N.: 1B, 3B
Relevant conflicts of interests/financial disclosures: Nothing to report.
Funding agency: This work was funded by the Laboratory of Cell Biology and Molecular Genetics, Department of Biology, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco.
References
- 1. Benítez‐Burraco A, Herrera E, Cuetos F. A core deficit in Parkinson disease? Neurol 2016;31:223–230. [DOI] [PubMed] [Google Scholar]
- 2. Shameli A, Xiao W, Zheng Y, et al. A critical role for alpha‐synuclein in development and function of T lymphocytes. Immunobiology 2016;221:333–340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Beatman EL, Massey A, Shives KD, et al. Alpha‐synuclein expression restricts RNA viral infections in the brain. J Virol 2016;90:2767–2782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Stolzenberg E, Berry D, Yang D, et al. A role for neuronal alpha‐synuclein in gastrointestinal immunity. J Innate Immun 2017;9:456–463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Bantle CM, Phillips AT, Smeyne RJ, Rocha SM, Olson KE, Tjalkens RB. Infection with mosquito‐borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation. NPJ Park Dis 2019;5:1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Xiao W, Shameli A, Harding CV, Meyerson HJ, Maitta RW. Late stages of hematopoiesis and B cell lymphopoiesis are regulated by αsynuclein, a key player in Parkinson’s disease. Immunobiology 2014;219:836–844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Lesteberg KE, Beckham JD. Immunology of West Nile virus infection and the role of alpha‐synuclein as a viral restriction factor. Viral Immunol 2019;32:38–47. [DOI] [PubMed] [Google Scholar]
- 8. Labrie V, Brundin P. Alpha‐synuclein to the rescue: immune cell recruitment by alpha‐synuclein during gastrointestinal infection. J Innate Immun 2017;9:437–440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Massey AR, Beckham JD. Alpha‐synuclein, a novel viral restriction factor hiding in plain sight. DNA Cell Biol 2016;35:643–645. [DOI] [PubMed] [Google Scholar]
- 10. Streit WJ, Mrak RE, Griffin WST. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 2004;1. 10.1186/1742-2094-1-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Austin SA, Floden AM, Murphy EJ, Combs CK. α‐Synuclein expression modulates microglial activation phenotype. J Neurosci 2006;26:10558–10563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Austin SA, Rojanathammanee L, Golovko MY, Murphy EJ, Combs CK. Lack of alpha‐synuclein modulates microglial phenotype in vitro. Neurochem Res 2011;36:994–1004. [DOI] [PubMed] [Google Scholar]
- 13. Serrano‐Castro PJ, Estivill‐Torrús G, Cabezudo‐García P. Influencia de la infección SARS‐CoV‐2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada? Neurología 2020;35:245–251. 10.1016/j.nrl.2020.04.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID‐19 and other coronaviruses [published online ahead of print 2020]. Brain Behav Immun. 10.1016/j.bbi.2020.03.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Wang H‐Y, Li X‐L, Yan Z‐R, et al. Potential neurological symptoms of COVID‐19. Ther Adv Neurol Disord 2020;13. https://doi.org/10.1177/1756286420917830 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Azhideh A. COVID‐19 neurological manifestations. Int Clin Neurosci J 2020;7:54. [Google Scholar]
- 17. Jo T, Yasunaga H, Michihata N, et al. Influence of Parkinsonism on outcomes of elderly pneumonia patients. Parkinson Relat Disord 2018;54:25–29. [DOI] [PubMed] [Google Scholar]